RAS oncogenes: weaving a tumorigenic web
Open accessThe DOI matches its Crossref record; 243 of the 243 references it cites were found in a registry or an index.
Abstract
RAS proteins are essential components of signalling pathways that emanate from cell surface receptors. Oncogenic activation of these proteins owing to missense mutations is frequently detected in several types of cancer. A wealth of biochemical and genetic studies indicates that RAS proteins control a complex molecular circuitry that consists of a wide array of interconnecting pathways. In this Review, we describe how RAS oncogenes exploit their extensive signalling reach to affect multiple cellular processes that drive tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Obviously, the RAF-MEK-ERK pathway is not the only pathway controlled by KRAS, 18 which is supported by findings demonstrating enhanced efficacy of combining MEK inhibitors with phosphoinositide 3-kinase inhibitors in NSCLC models.19,20”
From K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways (2019) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Mutations in G12, G13, or Q61 residue in the active site can lock KRAS in the GTP-bound form by impeding the hydrolysis to GDP catalyzed by GAPs, thus keeping downstream signaling constitutively active [16, 17].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [17]
In the citing paper
“PDEδ has a large hydrophobic pocket that can bind farnesyl proteins, especially the lipid portion of KRAS protein, thereby preventing the farnesyl modification of KRAS protein from binding to cell membrane and inhibiting tumor cell proliferation and growth.339,340”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [340]
In the citing paper
“The resulting RAS-mediated signaling cascades drive tumor initiation, maintenance and progression by deregulating key cellular processes, for instance by increasing proliferation and suppressing apoptosis, but also by rewiring cellular metabolism and promoting alterations in the tumor microenvironment3.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [3]
In the citing paper
“By constitutively activating these pathways, the Ras oncoprotein confers growth, survival and metastatic advantages to the cancer cell (11).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [11]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“To accommodate the emergence of additional cancer-associated pathologies this list has been increased to include additional hallmarks such as metabolic fitness and genomic plasticit”
BackgroundHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“These unique metabolic needs were first described in the 1920s by Otto Warburg and are typified by an increase in glucose uptake and a shift from mitochondrial oxidative phosphorylation to aerobic glycolysi”
BackgroundAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Disruption of epithelial cell-matrix interactions induces apoptosis
Frisch, S., & Francis, H. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.4.619 · Cited by 3,254
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797 · cited 1×
“Hence, the modification of the surrounding ECM is necessary both for the growth factors to reach the target endothelium and for the migration of the newly generated endothelium into the tumou”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“An inevitable consequence of the persistent mitogenic stimulation that is imposed by RAS is the initiation of replicative stress, which is marked by increased numbers of active DNA replication origins and collapsed replication forks, which ultimately leads to DNA damage and the activation of the DNA damage response (D…”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Cited by
Items 101–200 of 1,003
Genetically engineered pigs as models for human disease
Perleberg, C., Kind, A., & Schnieke, A. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.030783 · Cited by 222
“…mutations KRASG12D (Li et al., 2015; Schook et al., 2015) and TP53R167H (Leuchs et al., 2012; Schook et al., 2015), a mutation that is orthologous to the human R175H TP53 mutation; both of these represent mutations commonly found in human cancer (Levine and Oren, 2009; Pylayeva-Gupta et al., 2011).”
BackgroundMazhab-Jafari, M. T., Marshall, C. B., Smith, M. J., Gasmi-Seabrook, G. M. C., Stathopulos, P. B., Inagaki, F., Kay, L. E., Neel, B. G., & Ikura, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419895112 · Cited by 220
“Finally, K-RAS4B, a well-validated oncogenic driver for many cancer types, is a challenging drug target (16).”
BackgroundJeong, W.-J., Ro, E. J., & Choi, K.-Y. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0049-y · Cited by 220
Small-molecule modulation of Ras signaling
Spiegel, J., Cromm, P. M., Zimmermann, G., Grossmann, T. N., & Waldmann, H. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1560 · Cited by 214
Wright, H. J., Hou, J., Xu, B., Cortez, M., Potma, E. O., Tromberg, B. J., & Razorenova, O. V. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703791114 · Cited by 210
“In this respect, we recently established UCI-082014 from a primary tumor specimen and they are still to be characterized for driver mutations; MDA-MB-231 harbor mutations in BRAF and KRAS, which are potent inducers of tumor growth (69, 70).”
MethodYoung, A., Lou, D., & McCormick, F. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0231 · Cited by 211
“Oncogenic mutation in any one of the three RAS genes is thought to be sufficient to constitutively activate downstream signaling and confer independence from upstream growth cues (8).”
Canonical Wnt Signaling Is Required for Pancreatic Carcinogenesis
Zhang, Y., Morris, J. P., Yan, W., Schofield, H. K., Gurney, A., Simeone, D. M., Millar, S. E., Hoey, T., Hebrok, M., & Pasca di Magliano, M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4384 · Cited by 208
Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
Shimamura, T., Chen, Z., Soucheray, M., Carretero, J., Kikuchi, E., Tchaicha, J. H., Gao, Y., Cheng, K. A., Cohoon, T. J., Qi, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3904 · Cited by 202
“Approximately, 15% to 30% of patients with human non–small cell lung cancer (NSCLC) harbor an oncogenic KRAS mutation associated with resistance to conventional treatment regimens (1).”
BackgroundArtemenko, Y., Lampert, T. J., & Devreotes, P. N. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1638-8 · Cited by 200
“Leukocytes In mammalian cells Ras oncogenes are well known to regulate proliferation, cell growth, survival, and energy metabolism; however, Ras involvement in leukocyte chemotaxis has not been extensively studied [65].”
BackgroundInflammatory networks and immune surveillance of pancreatic carcinoma
Vonderheide, R. H., & Bayne, L. J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.01.006 · Cited by 200
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Molina-Arcas, M., Moore, C., Rana, S., van Maldegem, F., Mugarza, E., Romero-Clavijo, P., Herbert, E., Horswell, S., Li, L.-S., Janes, M. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7999 · Cited by 203
(2015) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-62702-5.00004-4 · Cited by 194
Santoni-Rugiu, E., Melchior, L. C., Urbanska, E. M., Jakobsen, J. N., de Stricker, K., Grauslund, M., & Sørensen, J. B. (2019) · Cancers · doi:10.3390/cancers11070923 · Cited by 194
Cancer Metabolism and the Evasion of Apoptotic Cell Death
Sharma, A., Boise, L., & Shanmugam, M. (2019) · Cancers · doi:10.3390/cancers11081144 · Cited by 185
MEK inhibitor resistance mechanisms and recent developments in combination trials
Kun, E., Tsang, Y. T. M., Ng, C. W., Gershenson, D. M., & Wong, K. K. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102137 · Cited by 184
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
Roskoski, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.013 · Cited by 194
Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
Burns, M. C., Sun, Q., Daniels, R. N., Camper, D., Kennedy, J. P., Phan, J., Olejniczak, E. T., Lee, T., Waterson, A. G., Rossanese, O. W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315798111 · Cited by 199
“Active Ras endows cells with capabilities that represent the hallmarks of cancer, including the ability to proliferate, evade programmed cell death, alter metabolism, induce angiogenesis, increase invasion and metastasis, and evade immune destruction (4).”
BackgroundActivation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth
Sangodkar, J., Perl, A., Tohme, R., Kiselar, J., Kastrinsky, D. B., Zaware, N., Izadmehr, S., Mazhar, S., Wiredja, D. D., O’Connor, C. M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89548 · Cited by 196
“KRAS signaling is altered in about 20% of human cancers (26, 27).”
BackgroundThe Ras Superfamily of Small GTPases: The Unlocked Secrets
Goitre, L., Trapani, E., Trabalzini, L., & Retta, S. F. (2014) · Methods in Molecular Biology · doi:10.1007/978-1-62703-791-4_1 · Cited by 182
Oncogenic Kras drives invasion and maintains metastases in colorectal cancer
Boutin, A. T., Liao, W.-T., Wang, M., Hwang, S. S., Karpinets, T. V., Cheung, H., Chu, G. C., Jiang, S., Hu, J., Chang, K., et al. (2017) · Genes & Development · doi:10.1101/gad.293449.116 · Cited by 195
“…– ERK components could be the result of a nonessential role for KRAS mut in CRC maintenance, the plethora of pathways downstream from activated KRAS (Pylayeva-Gupta et al. 2011), the existence of alternative KRAS-independent proliferation/ survival signaling pathways such as YAP (Kapoor et al.…”
Jeong, W.-J., Yoon, J., Park, J.-C., Lee, S.-H., Lee, S.-H., Kaduwal, S., Kim, H., Yoon, J.-B., & Choi, K.-Y. (2012) · Science Signaling · doi:10.1126/scisignal.2002242 · Cited by 188
FOXM1 (Forkhead box M1) in Tumorigenesis
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00016-2 · Cited by 184
“…et al., 2010; Maurer et al., 2011; McCormick, 2011; McCubrey et al., 2007, 2011; Mitsiades et al., 2004; Platanias, 2003; Pratilas and Solit, 2010; Pylayeva-Gupta et al., 2011; Roberts and Der, 2007; Sansal and Sellers, 2004; Schubbert et al., 2007; Sebolt-Leupold and Herrera, 2004; Steelman et…”
Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance
Castellano, E., Sheridan, C., Thin, M. Z., Nye, E., Spencer-Dene, B., Diefenbacher, M. E., Moore, C., Kumar, M. S., Murillo, M. M., Grönroos, E., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.012 · Cited by 182
Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view
Lu, S., Jang, H., Gu, S., Zhang, J., & Nussinov, R. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00911a · Cited by 188
Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series
Ciampi, R., Mian, C., Fugazzola, L., Cosci, B., Romei, C., Barollo, S., Cirello, V., Bottici, V., Marconcini, G., Rosa, P. M., et al. (2013) · Thyroid · doi:10.1089/thy.2012.0207 · Cited by 178
“Activating point mutations in RAS genes confer constitutive activation of multiple downstream effectors and have been extensively described in several tumor types (13,14).”
Extracellular vesicles – vehicles that spread cancer genes
Rak, J., & Guha, A. (2012) · BioEssays · doi:10.1002/bies.201100169 · Cited by 184
“the ability to stimulate angiogenesis or to metastasize [4, 11, 12].”
BackgroundRAS-mediated oncogenic signaling pathways in human malignancies
Khan, A. Q., Kuttikrishnan, S., Siveen, K. S., Prabhu, K. S., Shanmugakonar, M., Al- Naemi, H. A., Haris, M., Dermime, S., & Uddin, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.03.001 · Cited by 179
Vallejo, A., Perurena, N., Guruceaga, E., Mazur, P. K., Martinez-Canarias, S., Zandueta, C., Valencia, K., Arricibita, A., Gwinn, D., Sayles, L. C., et al. (2017) · Nature Communications · doi:10.1038/ncomms14294 · Cited by 181
Kaiser, C. E., Van Ert, N. A., Agrawal, P., Chawla, R., Yang, D., & Hurley, L. H. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b02046 · Cited by 179
RAC1 P29S is a spontaneously activating cancer-associated GTPase
Davis, M. J., Ha, B. H., Holman, E. C., Halaban, R., Schlessinger, J., & Boggon, T. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220895110 · Cited by 180
“3) (36) and mediate their oncogenic potential through the inability of Ras to hydrolyze GTP to GDP, therefore locking the GTPase in an activated state with consequent effector activation (36).”
BackgroundThe Transcription Factor FOXM1 (Forkhead box M1)
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407173-5.00004-2 · Cited by 176
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
Wei, D., Wang, L., Zuo, X., Maitra, A., & Bresalier, R. S. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2098 · Cited by 192
Pancreatic Cancer, Inflammation, and Microbiome
Zambirinis, C. P., Pushalkar, S., Saxena, D., & Miller, G. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000045 · Cited by 169
“There seems to be a cooperative relationship between Kras activation and inflammation.(12,13) Specifically, p48;LsL-Kras (“KC”) mice, which have mutant Kras expressed prenatally in all exocrine pancreatic lineages, exhibit pancreatitis as one of the earliest morphologic changes in their pancreas.”
BackgroundNew insights into designing hybrid nanoparticles for lung cancer: Diagnosis and treatment
Mottaghitalab, F., Farokhi, M., Fatahi, Y., Atyabi, F., & Dinarvand, R. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.009 · Cited by 171
The current understanding on the impact of KRAS on colorectal cancer
Meng, M., Zhong, K., Jiang, T., Liu, Z., Kwan, H. Y., & Su, T. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111717 · Cited by 171
Reiner, D. J., & Lundquist, E. A. (2018) · WormBook · doi:10.1895/wormbook.1.67.2 · Cited by 193
“Oncogenic activating mutations in Ras have mutations at positions 12, 13, and 61 as canonical activating mutations, with different alleles predominating in different tumor types (Pylayeva-Gupta et al., 2011 PMID: 21993244).”
BackgroundNeutrophils promote tumor resistance to radiation therapy
Wisdom, A. J., Hong, C. S., Lin, A. J., Xiang, Y., Cooper, D. E., Zhang, J., Xu, E. S., Kuo, H.-C., Mowery, Y. M., Carpenter, D. J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901562116 · Cited by 161
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Downward, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2180 · Cited by 166
“Extensive sequencing of human tumors has shown that KRAS is the most frequently mutated dominant oncogenic driver in human cancer, with activating mutations in one or another RAS family member being found in about 20% of human tumors (1, 2).”
BackgroundKnight, T., & Irving, J. A. E. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00160 · Cited by 164
Identification of pyrazolopyridazinones as PDEδ inhibitors
Papke, B., Murarka, S., Vogel, H. A., Martín-Gago, P., Kovacevic, M., Truxius, D. C., Fansa, E. K., Ismail, S., Zimmermann, G., Heinelt, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11360 · Cited by 160
Exosomes as Biomarkers for Female Reproductive Diseases Diagnosis and Therapy
Esfandyari, S., Elkafas, H., Chugh, R. M., Park, H.-S., Navarro, A., & Al-Hendy, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042165 · Cited by 166
Kitai, H., Ebi, H., Tomida, S., Floros, K. V., Kotani, H., Adachi, Y., Oizumi, S., Nishimura, M., Faber, A. C., & Yano, S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1377 · Cited by 162
“KRAS is the most frequently mutated oncogene in non-small-cell lung cancer (NSCLC), which is detected in 20 to 25% of Caucasian patients with lung adenocarcinoma (1,2).”
BackgroundSRF Co-factors Control the Balance between Cell Proliferation and Contractility
Gualdrini, F., Esnault, C., Horswell, S., Stewart, A., Matthews, N., & Treisman, R. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.10.016 · Cited by 161
“Ras activation stimulates cell-cycle re-entry from quiescence, and Ras genes are mutated in around 20% of human cancers (Chambard et al., 2007; Pylayeva-Gupta et al., 2011).”
BackgroundA Genetic Porcine Model of Cancer
Schook, L. B., Collares, T. V., Hu, W., Liang, Y., Rodrigues, F. M., Rund, L. A., Schachtschneider, K. M., Seixas, F. K., Singh, K., Wells, K. D., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128864 · Cited by 168
“In this study, we have targeted the RAS gene which is mutated in one quarter of all human cancers, with the KRAS isoform being the most commonly mutated [7] yielding a constitutively active, oncogenic protein [7] that experimentally induces cancer in mice [8] and human cells [9], in addition to underlying a number of…”
BackgroundMolina-Arcas, M., Hancock, D. C., Sheridan, C., Kumar, M. S., & Downward, J. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0446 · Cited by 157
“This poses a significant therapeutic challenge, as KRAS mutations are generally associated with resistance to existing therapies (4, 5).”
The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2
Kovalski, J. R., Bhaduri, A., Zehnder, A. M., Neela, P. H., Che, Y., Wozniak, G. G., & Khavari, P. A. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.12.001 · Cited by 154
“mTORC2 is Required for Ras Cell Cycle Gene Regulation The observation that MT Ras binds and enables mTORC2 activity suggested that mTORC2 might enable Ras impacts in cancer, prominent among which are downstream gene regulation (Pylayeva-Gupta et al., 2011).”
BackgroundSmall Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes
Herrero, A., Pinto, A., Colón‐Bolea, P., Casar, B., Jones, M., Agudo‐Ibáñez, L., Vidal, R., Tenbaum, S. P., Nuciforo, P. G., Valdizán, E. M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.001 · Cited by 165
ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma
Yoo, J. H., Shi, D., Grossmann, A. H., Sorensen, L. K., Tong, Z., Mleynek, T., Rogers, A., Zhu, W., Richards, J. R., Winter, J. M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.015 · Cited by 164
Drp1 Promotes KRas-Driven Metabolic Changes to Drive Pancreatic Tumor Growth
Nagdas, S., Kashatus, J. A., Nascimento, A., Hussain, S. S., Trainor, R. E., Pollock, S. R., Adair, S. J., Michaels, A. D., Sesaki, H., Stelow, E. B., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.031 · Cited by 146
“This initiates a variety of processes that are critical for tumor growth, including proliferation, survival, and evasion of immune destruction (Hanahan and Weinberg, 2011; Pylayeva-Gupta et al., 2011).”
BackgroundExploiting the therapeutic implications of KRAS inhibition on tumor immunity
Molina-Arcas, M., & Downward, J. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.012 · Cited by 152
Flex, E., Jaiswal, M., Pantaleoni, F., Martinelli, S., Strullu, M., Fansa, E. K., Caye, A., De Luca, A., Lepri, F., Dvorsky, R., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu148 · Cited by 144
A new link between diabetes and cancer: enhanced WNT/β-catenin signaling by high glucose
García-Jiménez, C., García-Martínez, J. M., Chocarro-Calvo, A., & De la Vieja, A. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-13-0152 · Cited by 151
“(Pylayeva-Gupta et al. 2011).”
Rare Codons Regulate KRas Oncogenesis
Lampson, B. L., Pershing, N. L. K., Prinz, J. A., Lacsina, J. R., Marzluff, W. F., Nicchitta, C. V., MacAlpine, D. M., & Counter, C. M. (2013) · Current Biology · doi:10.1016/j.cub.2012.11.031 · Cited by 148
“Oncogenic mutations in the small Ras GTPases KRas, HRas, or NRas render the encoded proteins constitutively GTP-bound and active, which promote cancer [1].”
Redox control of glutamine utilization in cancer
Alberghina, L., & Gaglio, D. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.513 · Cited by 147
Hashimoto, S., Furukawa, S., Hashimoto, A., Tsutaho, A., Fukao, A., Sakamura, Y., Parajuli, G., Onodera, Y., Otsuka, Y., Handa, H., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901765116 · Cited by 149
Characteristics of Lung Cancers Harboring NRAS Mutations
Ohashi, K., Sequist, L. V., Arcila, M. E., Lovly, C. M., Chen, X., Rudin, C. M., Moran, T., Camidge, D. R., Vnencak-Jones, C. L., Berry, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3173 · Cited by 142
“Although the 3 family members share conserved sequences, their protein products generate distinct signal outputs (25, 26) and have distinct roles in development (27, 28) and tumorigenesis in mice (29, 30).”
Zhang, X., Qi, Z., Yin, H., & Yang, G. S. (2019) · Theranostics · doi:10.7150/thno.29673 · Cited by 160
“RAS mutations in codons 12, 13, and 61 have been identified as the most activated forms inducing cell malignancy [6].”
BackgroundMorkel, M., Riemer, P., Bläker, H., & Sers, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4750 · Cited by 144
“KRAS, a small GTPase, acts as a central relay for signals originating at receptor tyrosine kinases such as the EGFR family in the intestinal epithelium and in many other tissues [3].”
BackgroundShin, S., Choi, D.-K., Jung, K., Bae, J., Kim, J., Park, S.-W., Song, K.-H., & Kim, Y. (2017) · Nature Communications · doi:10.1038/ncomms15090 · Cited by 149
Oncogenic K-Ras requires activation for enhanced activity
Huang, H., Daniluk, J., Liu, Y., Chu, J., Li, Z., Ji, B., & Logsdon, C. D. (2014) · Oncogene · doi:10.1038/onc.2012.619 · Cited by 140
The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform
Schachtschneider, K. M., Schwind, R. M., Newson, J. L., Kinachtchouk, N., Rizko, M., Mendoza-Elias, N., Grippo, P. J., Principe, D. R., Park, A. J., Overgaard, N. H., et al. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00190 · Cited by 150
“The KRASG12D and TP53R167H mutations were chosen because the resulting amino acid substitutions are commonly found in human cancers, with RAS and TP53 mutated in one-quarter and one-third of all human cancers, respectively (88, 89).”
BackgroundA single H/ACA small nucleolar RNA mediates tumor suppression downstream of oncogenic RAS
McMahon, M., Contreras, A., Holm, M., Uechi, T., Forester, C. M., Pang, X., Jackson, C., Calvert, M. E., Chen, B., Quigley, D. A., et al. (2019) · eLife · doi:10.7554/elife.48847 · Cited by 136
“To investigate the role of H/ACA snoRNAs during the earliest cellular response to oncogene activation, we interrogated the expression of ~90 H/ACA snoRNAs in primary human skin fibroblasts using a snoRNA quantitative PCR (qPCR) array, in the context of oncogene-induced senescence (OIS) by expression of RAS (Pylayeva-G…”
MethodThe epithelial–mesenchymal plasticity landscape: principles of design and mechanisms of regulation
Haerinck, J., Goossens, S., & Berx, G. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00601-0 · Cited by 156
Grabocka, E., Pylayeva-Gupta, Y., Jones, M. J. K., Lubkov, V., Yemanaberhan, E., Taylor, L., Jeng, H. H., & Bar-Sagi, D. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.005 · Cited by 145
“More recently, the Raf/MAPK pathway has been shown to impair Chk1 activity through Chk1 Ser 280 phosphorylation by MAPK-activated protein kinase RSK (p90 ribosomal S6 kinase) (Li et al., 2012; Ray-David et al., 2012).”
Self-citationAntitumor Activity in RAS -Driven Tumors by Blocking AKT and MEK
Tolcher, A. W., Khan, K., Ong, M., Banerji, U., Papadimitrakopoulou, V., Gandara, D. R., Patnaik, A., Baird, R. D., Olmos, D., Garrett, C. R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1901 · Cited by 137
“Ras signaling may be activated through direct interactions with numerous growth factor receptors, or independently stimulated by somatically acquired mutations in approximately 20% of human cancers, making this protein an important therapeutic target (1, 2).”
BackgroundRozengurt, E., Sinnett-Smith, J., & Eibl, G. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-017-0005-2 · Cited by 137
Treatment of NRAS-mutant melanoma
Johnson, D. B., & Puzanov, I. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0330-z · Cited by 139
Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
Uras, I. Z., Moll, H. P., & Casanova, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124325 · Cited by 135
The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor
McLaughlin, S. K., Olsen, S. N., Dake, B., De Raedt, T., Lim, E., Bronson, R. T., Beroukhim, R., Polyak, K., Brown, M., Kuperwasser, C., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.004 · Cited by 135
“Mutations in RAS genes occur in a variety of tumor types (Karnoub and Weinberg, 2008; Pylayeva-Gupta et al., 2011); however, the Ras pathway is also frequently activated as a consequence of alterations in upstream regulators and downstream effectors, underscoring the importance of this pathway in cancer (Downward, 200…”
BackgroundPotent and Selective Covalent Quinazoline Inhibitors of KRAS G12C
Zeng, M., Lu, J., Li, L., Feru, F., Quan, C., Gero, T. W., Ficarro, S. B., Xiong, Y., Ambrogio, C., Paranal, R. M., et al. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.06.017 · Cited by 136
Aredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., & Wakelee, H. A. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.015 · Cited by 132
Aytés, À., Mitrofanova, A., Kinkade, C. W., Lefèbvre, C., Lei, M., Phelan, V., Lekaye, C., Koutcher, J. A., Cardiff, R. D., Califano, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303558110 · Cited by 153
“Given the principal role of Ras signaling in metastases, combined with the fact that Ras signaling is generally refractory to conventional therapy (64, 65), targeting ETV4 in prostate cancer may provide an alternative means of inhibiting metastasis.”
BackgroundDai, C. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0525 · Cited by 143
A Perspective on Extracellular Vesicles Proteomics
Rosa-Fernandes, L., Bombarda-Rocha, V., Carregari, V. C., Urbani, A., & Palmisano, G. (2017) · Frontiers in Chemistry · doi:10.3389/fchem.2017.00102 · Cited by 142
“For example missense mutations in KRAS, which lock the protein into the GTP-bound state, occur in 30–40% of colorectal cancers (Pylayeva-Gupta et al., 2011).”
BackgroundCregg, J., Edwards, A. V., Chang, S., Lee, B. J., Knox, J. E., Tomlinson, A. C. A., Marquez, A., Liu, Y., Freilich, R., Aay, N., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02314 · Cited by 151
The role of wild type RAS isoforms in cancer
Zhou, B., Der, C. J., & Cox, A. D. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.07.012 · Cited by 130
“These results, along with a plethora of studies in which ectopic expression of wild type human RAS isoforms was sufficient to transform rodent fibroblasts to tumourigenicity [2, 3, 5], suggested that overexpression of wild type RAS alone could be sufficient to promote tumourigenicity, albeit with the caveat that too m…”
BackgroundResultMalinowska-Ozdowy, K., Frech, C., Schönegger, A., Eckert, C., Cazzaniga, G., Stanulla, M., Stadt, U. Z., Mecklenbräuker, A., Schuster, M. K., Kneidinger, D., et al. (2015) · Leukemia · doi:10.1038/leu.2015.107 · Cited by 132
Novel signaling axis for ROS generation during K-Ras-induced cellular transformation
Park, M.-T., Kim, M.-J., Suh, Y., Kim, R.-K., Kim, H., Lim, E.-J., Yoo, K.-C., Lee, G.-H., Kim, Y.-H., Hwang, S.-G., et al. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.34 · Cited by 131
GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors
Kazi, A., Xiang, S., Yang, H., Delitto, D., Trevino, J., Jiang, R. H. Y., Ayaz, M., Lawrence, H. R., Kennedy, P., & Sebti, S. M. (2018) · Nature Communications · doi:10.1038/s41467-018-07644-6 · Cited by 122
The Importance of Being PI3K in the RAS Signaling Network
Cuesta, C., Arévalo-Alameda, C., & Castellano, E. (2021) · Genes · doi:10.3390/genes12071094 · Cited by 138
MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival
Lee, C.-S., Lee, L. C., Yuan, T. L., Chakka, S., Fellmann, C., Lowe, S. W., Caplen, N. J., McCormick, F., & Luo, J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817494116 · Cited by 126
“Gene symbol abbreviations: A, ARAF; a, RALA; B, BRAF; b, RALB; C, CRAF; K, KRAS; n, BECN1; p, RALBP1; 1, RAC1; 2, RAC2; 5, ATG5; 7, ATG7.”
BackgroundInfluentialThe complex landscape of pancreatic cancer metabolism
Sousa, C. M., & Kimmelman, A. C. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu097 · Cited by 120
The impact of the Cancer Genome Atlas on lung cancer
Chang, J. T.-H., Lee, Y. M., & Huang, R. S. (2015) · Translational research · doi:10.1016/j.trsl.2015.08.001 · Cited by 141
“[22] Mutation in KRAS is not an independent mutation that singularly drives carcinogenesis, but is often associated with mutations in the CDKN2AB locus as well.”
BackgroundMutant KRAS as a critical determinant of the therapeutic response of colorectal cancer
Knickelbein, K., & Zhang, L. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2014.10.002 · Cited by 117
Oncogenic Ras Isoforms Signaling Specificity at the Membrane
Nussinov, R., Tsai, C.-J., & Jang, H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2727 · Cited by 122
Makino, Y., Hikita, H., Kodama, T., Shigekawa, M., Yamada, R., Sakamori, R., Eguchi, H., Morii, E., Yokoi, H., Mukoyama, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3844 · Cited by 128
“Although various genemutations were reported to be observed in human HCC (29), the frequency of Kras mutations is not high and has been reported to be approximately 5% to 7% (30).”
BackgroundHu, C.-M., Tien, S.-C., Hsieh, P.-K., Jeng, Y.-M., Chang, M.-C., Chang, Y.-T., Chen, Y.-J., Chen, Y.-J., Lee, E. Y.-H. P., & Lee, W.-H. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.005 · Cited by 123
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors
Lv, X., Lu, X., Cao, J., Luo, Q., Ding, Y., Peng, F., Pataer, A., Lu, D., Han, D., Malmberg, E., et al. (2023) · Science · doi:10.1126/science.abn4180 · Cited by 123
Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators
Wang, Y., Kaiser, C. E., Frett, B., & Li, H.-Y. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3017706 · Cited by 121
Meyer, M. J., Lapcevic, R., Romero, A. E., Yoon, M., Das, J., Beltrán, J. F., Mort, M., Stenson, P. D., Cooper, D. N., Paccanaro, A., et al. (2016) · Human Mutation · doi:10.1002/humu.22963 · Cited by 125
“In fact, it has long been known that substitutions in these codons induce tumorigenesis, and several mechanisms have been proposed [Pylayeva-Gupta et al., 2011] (Supp.”
BackgroundHerling, C., Klaumuenzer, M., Rocha, C. K., Altmüller, J., Thiele, H., Bahlo, J., Kluth, S., Crispatzu, G., Herling, M., Schiller, J., et al. (2016) · Blood · doi:10.1182/blood-2016-01-691550 · Cited by 131
“KRAS, aswell asNRAS, belong to theMAPK-ERK signaling pathway,which represents an important effector pathway of the B-cell receptor.(41) Large-scale exome/genome sequencing studies have obtained variable frequencies of mutant KRAS, the highest fraction (14 patients, 2.”
BackgroundSchlitter, A. M., Segler, A., Steiger, K., Michalski, C. W., Jäger, C., Konukiewitz, B., Pfarr, N., Endris, V., Bettstetter, M., Kong, B., et al. (2017) · Scientific Reports · doi:10.1038/srep41064 · Cited by 112
Amino acid management in cancer
Tsun, Z.-Y., & Possemato, R. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.08.002 · Cited by 112
Regulation of RAS oncogenicity by acetylation
Yang, M. H., Nickerson, S., Kim, E. T., Liot, C., Laurent, G., Spang, R., Philips, M. R., Shan, Y., Shaw, D. E., Bar-Sagi, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201487109 · Cited by 122
“RAS family members are among the most commonly mutated oncoproteins in human cancers (22).”
BackgroundSelf-citationJerchel, I. S., Hoogkamer, A. Q., Ariës, I. M., Steeghs, E. M. P., Boer, J. M., Besselink, N. J. M., Boeree, A., van de Ven, C., de Groot‐Kruseman, H. A., de Haas, V., et al. (2017) · Leukemia · doi:10.1038/leu.2017.303 · Cited by 128
“7,8,49 Recent reports suggest that RAS pathway mutations are recurrent in pediatric BCP-ALL.”
Roskoski, R. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.009 · Cited by 119
IL-1R–MyD88 signaling in keratinocyte transformation and carcinogenesis
Cataisson, C., Salcedo, R., Hakim, S., Moffitt, B. A., Wright, L., Yi, M., Stephens, R., Dai, R.-M., Lyakh, L., Schenten, D., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20101355 · Cited by 113
Tidyman, W. E., & Rauen, K. A. (2016) · Current Genetic Medicine Reports · doi:10.1007/s40142-016-0100-7 · Cited by 112
Smurfs in Protein Homeostasis, Signaling, and Cancer
Koganti, P., Levy‐Cohen, G., & Blank, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00295 · Cited by 120
The many substrates and functions of NEDD4-1
Huang, X., Chen, J., Cao, W., Yang, L., Chen, Q., He, J., Yi, Q., Huang, H., Zhang, E., & Cai, Z. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2142-8 · Cited by 119
Metadata
- Authors
- Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D.
- Affiliations
- New York University (US)
- ORCID
- Grabocka, Elda
- Venue
- Nature Reviews Cancer
- Published
- 2011-10-13
- Volume
- 11
- Issue
- 11
- Pages
- 761-774
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3632399
- OpenAlex
- W1970527559
- Cited by
- 1,789
- References
- 239
- Citations by year
- 2026: 78 · 2025: 95 · 2024: 108 · 2023: 109 · 2022: 123 · 2021: 154 · 2020: 113 · 2019: 144 · 2018: 124 · 2017: 143 · 2016: 156 · 2015: 139 · 2014: 123 · 2013: 111 · 2012: 59
- FWCI
- 8.51
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Research Institute
- National Cancer Institute (R01CA055360, 1F32CA13922, CA 055360, R37CA055360, R56CA055360)
- National Institute of General Medical Sciences (R01GM078266, GM078266)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, oncogenic Ras mutations, carcinogenesis, Ras isoforms, missense mutations, cell-autonomous effects, non-cell-autonomous effects, signaling pathways, cancer
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasm Metastasis, Genes, ras, Apoptosis, Mutation, Missense, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.